scholarly journals Effects of High-Frequency Cranial Electrostimulation on the Rest-Activity Rhythm and Salivary Cortisol in Alzheimer’s Disease

2006 ◽  
Vol 22 (4) ◽  
pp. 267-272 ◽  
Author(s):  
Erik Scherder ◽  
Dirk Knol ◽  
Marie-Jose van Tol ◽  
Eus van Someren ◽  
Jan-Berend Deijen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Salivary Cortisol ◽  
High Frequency ◽  
Activity Rhythm ◽  
Rest Activity

scholarly journals Effects of Low-Frequency Cranial Electrostimulation on the Rest-Activity Rhythm and Salivary Cortisol in Alzheimer's Disease

2003 ◽  
Vol 17 (2) ◽  
pp. 101-108 ◽  
Author(s):  
Erik Scherder ◽  
Dirk Knol ◽  
Eus van Someren ◽  
Jan-Berend Deijen ◽  
Rob Binnekade ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Activity Rhythm ◽  
Low Frequency ◽  
Control Group ◽  
Positive Effects ◽  
Alternative Research ◽  
Positive Effect ◽  
Experimental Group ◽  
Rest Activity

Objective. In previous studies, cranial electrostimulation (CES) had positive effects on sleep in depressed patients and in patients with vascular dementia. The present study examined the effects of low-frequency CES on the rest-activity rhythm and cortisol levels of patients with probable Alzheimer's disease (AD). Method. It was hypothesised that a decreased level of cortisol would parallel a positive effect of low-frequency CES on nocturnal restlessness. Sixteen AD patients were randomly assigned to an experimental group (n = 8) or a control group (n = 8). The experimental group was treated with CES, whereas the control group received sham stimulation, for 30 minutes a day, during 6 weeks. The rest-activity rhythm was assessed by actigraphy. Cortisol was measured repeatedly in the saliva throughout the day by means of salivette tubes. Results. Low-frequency CES did not improve the rest-activity rhythm in AD patients. Moreover, both groups showed an increase instead of a decrease in the level of cortisol. Conclusions: These preliminary results suggest that low-frequency CES has no positive effect on the rest-activity rhythm in AD patients. An alternative research design with high-frequency CES in AD is discussed.

Effects of Melatonin in Two Individuals with Alzheimer's Disease

1998 ◽  
Vol 87 (1) ◽  
pp. 331-339 ◽  
Author(s):  
Girardin Jean-Louis ◽  
Ferdinand Zizi ◽  
Hans Von Gizycki ◽  
Harvey Taub
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Circadian Rhythm ◽  
Aging Process ◽  
Activity Rhythm ◽  
The Other ◽  
Beneficial Effects ◽  
Melatonin Administration ◽  
Activity Cycles ◽  
Rest Activity

Dementia has been associated with circadian rhythm disturbances expressed in several dimensions including body temperature, hormonal concentrations, sleep and wakefulness patterns, and rest-activity cycles. These disturbances may be the result of a dampening in the amplitude of the circadian rhythm. One of the symptoms associated with the aging process has been a decline in the amplitude of the melatonin rhythm. Here, the results of melatonin administration to two patients with Alzheimer's disease are presented. Melatonin administration enhanced and stabilized the circadian rest-activity rhythm in one of the patients along with some reduction of daytime sleepiness and an improvement in mood. The other patient, who was characterized by less cognitive impairment, showed no significant changes associated with melatonin ingestion. Interestingly, the acrophase of rest-activity was delayed for about one hour in both patients. These results suggest that melatonin may have beneficial effects in some patients with Alzheimer's disease

scholarly journals Circadian rest—activity rhythm disturbances in alzheimer's disease

1996 ◽  
Vol 40 (4) ◽  
pp. 259-270 ◽  
Author(s):  
Eus J.W. van Someren ◽  
Eveline E.O. Hagebeuk ◽  
Cees Lijzenga ◽  
Philip Scheltens ◽  
Sophie E.J.A. de Rooij ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Activity Rhythm ◽  
Rest Activity

scholarly journals Sleep and Diurnal Rest-Activity Rhythm Disturbances in a Mouse Model of Alzheimer’s Disease

2020 ◽  
Author(s):  
Mikolaj J. Filon ◽  
Eli Wallace ◽  
Samantha Wright ◽  
Dylan J. Douglas ◽  
Lauren I. Steinberg ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Rem Sleep ◽  
Activity Rhythm ◽  
Activity Levels ◽  
Wild Type ◽  
Drug Bioavailability ◽  
Activity Rhythms ◽  
Delta Power ◽  
Rest Activity

AbstractStudy ObjectivesAccumulating evidence suggests a strong association between sleep, amyloid-beta (Aβ) deposition, and Alzheimer’s disease (AD). We sought to determine if: (1) deficits in rest-activity rhythms and sleep are significant phenotypes in J20 AD mice, (2) metabotropic glutamate receptor 5 inhibitors (mGluR5) could rescue deficits in rest-activity rhythms and sleep, and (3) Aβ levels are responsive to treatment with mGluR5 inhibitors.MethodsDiurnal rest-activity levels were measured by actigraphy and sleep-wake patterns by electroencephalography (EEG), while animals were chronically treated with mGluR5 inhibitors. Behavioral tests were performed, and Aβ levels measured in brain lysates.ResultsJ20 mice exhibited a 4.5 hour delay in the acrophase of activity levels compared to wild-type littermates, and spent less time in REM sleep during the second half of the light period. J20 mice also exhibited decreased NREM delta power but increased NREM sigma power. The mGluR5 inhibitor CTEP rescued the REM sleep deficit and improved NREM delta and sigma power but did not correct rest-activity rhythms. No statistically significant differences were observed in Aβ levels, rotarod performance or the passive avoidance task following chronic mGluR5 inhibitor treatment.ConclusionsJ20 mice have disruptions in rest-activity rhythms and reduced homeostatic sleep pressure (reduced NREM delta power). NREM delta power was increased following treatment with an mGluR5 inhibitor. Drug bioavailability was poor. Further work is necessary to determine if mGluR5 is a viable target for treating sleep phenotypes in AD.Statement of SignificanceSleep disruption is evolving as an important risk factor as well as phenotype of neurological diseases including Alzheimer’s disease. This study is novel in determining alterations in the rest-activity rhythm and sleep-wake pattern of J20 Alzheimer’s disease mice and wild type littermates. Specifically, there is a delay in acrophase with prolonged hyperactivity during the dark cycle, and reduced sleep pressure that was improved by treatment with mGluR5 inhibitor. Critical remaining knowledge gaps and future directions include testing the effects of Alzheimer’s disease drugs on rescue of sleep and rest-activity patterns in other Alzheimer’s disease models. These studies are relevant to human Alzheimer’s disease as monitoring sleep phenotypes may predict disease risk, and therapies that normalize sleep patterns may slow progression.

scholarly journals Peripheral electrical nerve stimulation and rest-activity rhythm in Alzheimer's disease

2006 ◽  
Vol 15 (4) ◽  
pp. 415-423 ◽  
Author(s):  
KOENE R. A. VAN DIJK ◽  
MARIJN W. LUIJPEN ◽  
EUS J. W. VAN SOMEREN ◽  
JOSEPH A. SERGEANT ◽  
PHILIP SCHELTENS ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nerve Stimulation ◽  
Activity Rhythm ◽  
Electrical Nerve Stimulation ◽  
Rest Activity

scholarly journals Effect of morning bright light treatment for rest–activity disruption in institutionalized patients with severe Alzheimer's disease

2005 ◽  
Vol 17 (2) ◽  
pp. 221-236 ◽  
Author(s):  
Glenna A. Dowling ◽  
Erin M. Hubbard ◽  
Judy Mastick ◽  
Jay S. Luxenberg ◽  
Robert L. Burr ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Light Exposure ◽  
Activity Rhythm ◽  
Bright Light ◽  
Wake Time ◽  
Institutionalized Patients ◽  
Nighttime Sleep ◽  
Bright Light Exposure ◽  
Rest Activity

Background: Disturbances in rest–activity rhythm are prominent and disabling symptoms in Alzheimer's disease (AD). Nighttime sleep is severely fragmented and daytime activity is disrupted by multiple napping episodes. In most institutional environments, light levels are very low and may not be sufficient to enable the circadian clock to entrain to the 24-hour day. The purpose of this randomized, placebo-controlled, clinical trial was to test the effectiveness of morning bright light therapy in reducing rest–activity (circadian) disruption in institutionalized patients with severe AD.Method: Subjects (n=46, mean age 84 years) meeting the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke – the Alzheimer's Disease and Related Disorders Association) AD diagnostic criteria were recruited from two large, skilled nursing facilities in San Francisco, California. The experimental group received one hour (09:30–10:30) of bright light exposure (≥2500lux in gaze direction) Monday through Friday for 10weeks. The control group received usual indoor light (150–200lux). Nighttime sleep efficiency, sleep time, wake time and number of awakenings and daytime wake time were assessed using actigraphy. Circadian rhythm parameters were also determined from the actigraphic data using cosinor analysis and nonparametric techniques. Repeated measures analysis of variance (ANOVA) was used to test the primary study hypotheses.Results and conclusion: Although significant improvements were found in subjects with aberrant timing of their rest–activity rhythm, morning bright light exposure did not induce an overall improvement in measures of sleep or the rest–activity in all treated as compared to control subjects. The results indicate that only subjects with the most impaired rest–activity rhythm respond significantly and positively to a brief (one hour) light intervention.

scholarly journals Alterations in the circadian rest-activity rhythm in aging and Alzheimer's disease

1990 ◽  
Vol 27 (6) ◽  
pp. 563-572 ◽  
Author(s):  
W. Witting ◽  
I.H. Kwa ◽  
P. Eikelenboom ◽  
M. Mirmiran ◽  
D.F. Swaab
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Activity Rhythm ◽  
Rest Activity

A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease

1993 ◽  
Vol 163 (2) ◽  
pp. 166-168 ◽  
Author(s):  
Akira Ueki ◽  
Mikihiko Kawano ◽  
Yoshio Namba ◽  
Masanobu Kawakami ◽  
Kazuhiko Ikeda
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
High Frequency ◽  
Late Onset ◽  
Japanese Patients ◽  
Apolipoprotein E4
Sign in / Sign up

Export Citation Format

Share Document